Rules regarding driver licensing of patients with OSAS should be implemented across Europe to prevent road accidents due to daytime sleepiness.

The number of centres able to diagnose and manage patients with OSAS needs to be increased.

The understanding of daytime somnolence and the methods necessary for its detection and assessment need to be improved.

nCPAP is a very effective but cumbersome treatment. A pharmacological alternative to nCPAP would help alleviate treatment.

Basic knowledge of the disease needs to be improved to enable development of simple, cost-effective and reliable screening tests to identify patients who would benefit from treatment.